New anemia drug candidate put to the test against market leader
NCT ID NCT06919861
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This trial compares a new erythropoietin drug called Nanokine to the approved drug Eprex in healthy male volunteers. The goal is to see if Nanokine is absorbed and processed by the body similarly to Eprex, and whether it has a comparable effect on red blood cell production. Each volunteer receives a single injection of both drugs, one after a 28-day break, and researchers measure drug levels and safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Erythropoietin alfa (Nanokine and Eprex)
- What this could lead to
- If Nanokine proves similar to Eprex, it could become a more affordable alternative for treating anemia.
- What could go wrong
- This is an early-phase study in healthy volunteers, so results may not predict effects in patients with anemia. The drug may still fail in later trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHARMACOKINETICS AND PHARMACODYNAMICS IN HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.